Challenges to the clinical application of pluripotent stem cells: Towards genomic and functional stability

Genome Medicine

Volumn 4, Issue 6, 2012, Pages

  Fu, Xuemei ^a,b   Xu, Yang ^b  

^a CHENGDU WOMEN S AND CHILDREN S CENTRAL HOSPITAL   (China)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cell therapy; Embryonic stem cells; Epigenetics; Genetic stability; Immune rejection; Induced pluripotent stem cells

Indexed keywords

AUTOIMMUNE DISEASE; CELL CULTURE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL RENEWAL; CHROMOSOME DELETION; CLINICAL ASSESSMENT; COMPARATIVE GENOMIC HYBRIDIZATION; CULTURE MEDIUM; DNA DAMAGE; EMBRYONIC STEM CELL; GENE AMPLIFICATION; GENETIC STABILITY; GENETICS; GENOMIC INSTABILITY; GENOMICS; GRAFT REJECTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGENICITY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RENEWABLE ENERGY; RETINA MACULA DEGENERATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC CELL; SPINAL CORD INJURY; TISSUE CULTURE;

EID: 84862732494     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm354     Document Type: Review

References (118)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
2. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, Reinecke H, Xu C, Hassanipour M, Police S, O'Sullivan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J, Murry CE. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007, 25:1015-1024. 10.1038/nbt1327, 17721512.
3. Xu C, Police S, Hassanipour M, Li Y, Chen Y, Priest C, O'Sullivan C, Laflamme MA, Zhu WZ, Van Biber B, Hegerova L, Yang J, Delavan-Boorsma K, Davies A, Lebkowski J, Gold JD. Efficient generation and cryopreservation of cardiomyocytes derived from human embryonic stem cells. Regen Med 2010, 6:53-66.
4. Marzorati S, Pileggi A, Ricordi C. Allogeneic islet transplantation. Expert Opin Biol Ther 2007, 7:1627-1645. 10.1517/14712598.7.11.1627, 17961088.
5. D'Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, Moorman MA, Kroon E, Carpenter MK, Baetge EE. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol 2006, 24:1392-1401. 10.1038/nbt1259, 17053790.
6. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H, Richardson M, Smart NG, Cunningham J, Agulnick AD, D'Amour KA, Carpenter MK, Baetge EE. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008, 26:443-452. 10.1038/nbt1393, 18288110.
7. Coutts M, Keirstead HS. Stem cells for the treatment of spinal cord injury. Exp Neurol 2008, 209:368-377. 10.1016/j.expneurol.2007.09.002, 17950280.
8. Solbakk JH, Zoloth L. The tragedy of translation: the case of 'first use' in human embryonic stem cell research. Cell Stem Cell 2011, 8:479-481. 10.1016/j.stem.2011.04.009, 21549323.
9. Schwartz SD, Hubschman J-P, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, Mickunas E, Gay R, Klimanskaya I, Lanza R. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012, 379:713-720. 10.1016/S0140-6736(12)60028-2, 22281388.
10. Lewitzky M, Yamanaka S. Reprogramming somatic cells towards pluripotency by defined factors. Curr Opin Biotechnol 2007, 18:467-473. 10.1016/j.copbio.2007.09.007, 18024106.
11. Fu X, Xu Y. Self-renewal and scalability of human embryonic stem cells for human therapy. Regen Med 2011, 6:327-334. 10.2217/rme.11.18, 21548738.
12. Si Y-L, Zhao Y-L, Hao H-J, Fu X-B, Han W-D. MSCs: biological characteristics, clinical applications and their outstanding concerns. Ageing Res Rev 2011, 10:93-103. 10.1016/j.arr.2010.08.005, 20727988.
13. Lunn JS, Sakowski SA, Federici T, Glass JD, Boulis NM, Feldman EL. Stem cell technology for the study and treatment of motor neuron diseases. Regen Med 2011, 6:201-213. 10.2217/rme.11.6, 3154698, 21391854.
14. Mitjavila-Garcia MT, Simonin C, Peschanski M. Embryonic stem cells: Meeting the needs for cell therapy. Adv Drug Deliv Rev 2005, 57:1935-1943.
15. Crook JM, Peura TT, Kravets L, Bosman AG, Buzzard JJ, Horne R, Hentze H, Dunn NR, Zweigerdt R, Chua F, Upshall A, Colman A. The generation of six clinical-grade human embryonic stem cell lines. Cell Stem Cell 2007, 1:490-494. 10.1016/j.stem.2007.10.004, 18938745.
16. Sivarajah S, Raj GS, Mathews AJV, Sahib NBE, Hwang WS, Crook JM. The generation of GLP-grade human embryonic stem cell banks from four clinical-grade cell lines for preclinical research. Vitro Cell Dev Biol Anim 2010, 46:210-216.
17. Englund MCO, Caisander G, Noaksson K, Emanuelsson K, Lundin K, Bergh C, Hansson C, Semb H, Strehl R, Hyllner J. The establishment of 20 different human embryonic stem cell lines and subclones; a report on derivation, culture, characterisation and banking. Vitro Cell Dev Biol Anim 2010, 46:217-230.
18. Aguilar-Gallardo C, Poo M, Gomez E, Galan A, Sanchez E, Marques-Mari A, Ruiz V, Medrano J, Riboldi M, Valbuena D, Simon C. Derivation, characterization, differentiation, and registration of seven human embryonic stem cell lines (VAL-3,-4,-5,-6M,-7,-8, and-9) on human feeder. Vitro Cell Dev Biol Anim 2010, 46:317-326.
19. Meng GL, Liu SY, Krawetz R, Chan M, Chernos J, Rancourt DE. A novel method for generating xeno-free human feeder cells for human embryonic stem cell culture. Stem Cells Dev 2008, 17:413-422. 10.1089/scd.2007.0236, 18513158.
20. Tecirlioglu RT, Nguyen L, Koh K, Trounson AO, Michalska AE. Derivation and maintenance of human embryonic stem cell line on human adult skin fibroblast feeder cells in serum replacement medium. Vitro Cell Dev Biol Anim 2010, 46:231-235.
21. Park Y, Choi IY, Lee SJ, Lee SR, Sung HJ, Kim JH, Yoo YD, Geum DH, Kim SH, Kim BS. Undifferentiated propagation of the human embryonic stem cell lines, H1 and HSF6, on human placenta-derived feeder cells without basic fibroblast growth factor supplementation. Stem Cells Dev 2010, 19:1713-1722. 10.1089/scd.2010.0014, 20201681.
22. Meng GL, Liu SY, Li XY, Krawetz R, Rancourt DE. Extracellular matrix isolated from foreskin fibroblasts supports long-term xeno-free human embryonic stem cell culture. Stem Cells Dev 2010, 19:547-556. 10.1089/scd.2009.0303, 19883201.
23. Meng Y, Eshghi S, Li YJ, Schmidt R, Schaffer DV, Healy KE. Characterization of integrin engagement during defined human embryonic stem cell culture. FASEB J 2010, 24:1056-1065. 10.1096/fj.08-126821, 2845424, 19933311.
24. Rodin S, Domogatskaya A, Strom S, Hansson EM, Chien KR, Inzunza J, Hovatta O, Tryggvason K. Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. Nat Biotechnol 2010, 28:611-615. 10.1038/nbt.1620, 20512123.
25. Prowse ABJ, Doran MR, Cooper-White JJ, Chong F, Munro TP, Fitzpatrick J, Chung T-L, Haylock DN, Gray PP, Wolvetang EJ. Long term culture of human embryonic stem cells on recombinant vitronectin in ascorbate free media. Biomaterials 2010, 31:8281-8288. 10.1016/j.biomaterials.2010.07.037, 20674971.
26. Ludwig TE, Bergendahl V, Levenstein ME, Yu J, Probasco MD, Thomson JA. Feeder-independent culture of human embryonic stem cells. Nat Methods 2006, 3:637-646. 10.1038/nmeth902, 16862139.
27. Wang L, Schulz TC, Sherrer ES, Dauphin DS, Shin S, Nelson AM, Ware CB, Zhan M, Song C-Z, Chen X, Brimble SN, McLean A, Galeano MJ, Uhl EW, D'Amour KA, Chesnut JD, Rao MS, Blau CA, Robins AJ. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling. Blood 2007, 110:4111-4119. 10.1182/blood-2007-03-082586, 2190616, 17761519.
28. Yao S, Chen S, Clark J, Hao E, Beattie GM, Hayek A, Ding S. Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions. Proc Natl Acad Sci USA 2006, 103:6907-6912. 10.1073/pnas.0602280103, 1458992, 16632596.
29. Melkoumian Z, Weber JL, Weber DM, Fadeev AG, Zhou YE, Dolley-Sonneville P, Yang JW, Qiu LQ, Priest CA, Shogbon C, Melkoumian Z, Weber JL, Weber DM, Fadeev AG, Zhou YE, Dolley-Sonneville P, Yang JW, Qiu LQ, Priest CA, Shogbon C. Synthetic peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. Nat Biotechnol 2010, 28:606-610. 10.1038/nbt.1629, 20512120.
30. Villa-Diaz LG, Nandivada H, Ding J, Nogueira-De-Souza NC, Krebsbach PH, O'Shea KS, Lahann J, Smith GD. Synthetic polymer coatings for long-term growth of human embryonic stem cells. Nat Biotechnol 2010, 28:581-583. 10.1038/nbt.1631, 20512122.
31. Serra M, Brito C, Sousa MFQ, Jensen J, Tosti{dotless}es R, Clemente J, Strehl R, Hyllner J, Carrondo MJT, Alves PM. Improving expansion of pluripotent human embryonic stem cells in perfused bioreactors through oxygen control. J Biotechnol 2010, 148:208-215. 10.1016/j.jbiotec.2010.06.015, 20600380.
32. Steiner D, Khaner H, Cohen M, Even-Ram S, Gil Y, Itsykson P, Turetsky T, Idelson M, Aizenman E, Ram R, Berman-Zaken Y, Reubinoff B. Derivation, propagation and controlled differentiation of human embryonic stem cells in suspension. Nat Biotechnol 2010, 28:361-388. 10.1038/nbt.1616, 20351691.
33. Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R, Lynch C, Harness JV, Lee S, Barrero MJ, Ku S, Martynova M, Semechkin R, Galat V, Gottesfeld J, Izpisua Belmonte JC, Murry C, Keirstead HS, Park HS, Schmidt U, Laslett AL, Muller FJ, Nievergelt CM, Shamir R, Loring JF. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011, 8:106-118. 10.1016/j.stem.2010.12.003, 3043464, 21211785.
34. Xu Y. A new role for p53 in maintaining genetic stability in embryonic stem cells. Cell Cycle 2005, 4:363-364. 10.4161/cc.4.3.1529, 15701975.
35. Xu Y. DNA damage: a trigger of innate immunity but a requirement for adaptive immune homeostasis. Nat Rev Immunol 2006, 6:261-270. 10.1038/nri1804, 16498454.
36. Song H, Chung SK, Xu Y. Modeling disease in human ESCs using an efficient BAC-based homologous recombination system. Cell Stem Cell 2010, 6:80-89. 10.1016/j.stem.2009.11.016, 20074536.
37. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431. 10.1016/j.cell.2009.04.037, 19410540.
38. Feng Z, Hu W, Rajagopal G, Levine AJ. The tumor suppressor p53: cancer and aging. Cell Cycle 2008, 7:842-847. 10.4161/cc.7.7.5657, 18414039.
39. Suzuki H, Miyazono K. Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. J Mol Med 2010, 88:1085-1094. 10.1007/s00109-010-0650-1, 20614100.
40. Momcilovic O, Choi S, Varum S, Bakkenist C, Schatten G, Navara C. Ionizing radiation induces ataxia telangiectasia mutated-dependent checkpoint signaling and cell cycle arrest in pluripotent human embryonic stem cells. Stem Cells 2009, 27:1822-1835. 10.1002/stem.123, 3340923, 19544417.
41. Song H, Chung S-K, Xu Y. Modeling disease in human ESCs using an efficient BAC-based homologous recombination system. Cell Stem Cell 2010, 6:80-89. 10.1016/j.stem.2009.11.016, 20074536.
42. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, Xu Y. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005, 7:165-171. 10.1038/ncb1211, 15619621.
43. Zhao T, Xu Y. p53 and stem cells: new developments and new concerns. Trends Cell Biol 2010, 20:170-175. 10.1016/j.tcb.2009.12.004, 20061153.
44. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002, 2:764-776. 10.1038/nrc904, 12360279.
45. Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer 2006, 6:11-23. 10.1038/nrc1780, 16372018.
46. Almstrup K, Hoei-Hansen CE, Wirkner U, Blake J, Schwager C, Ansorge W, Nielsen JE, Skakkebaek NE, Rajpert-De Meyts E, Leffers H. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res 2004, 64:4736-4743. 10.1158/0008-5472.CAN-04-0679, 15256440.
47. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005, 121:465-477. 10.1016/j.cell.2005.02.018, 15882627.
48. Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005, 104:2255-2265. 10.1002/cncr.21432, 16228988.
49. Hart AH, Hartley L, Parker K, Ibrahim M, Looijenga LH, Pauchnik M, Chow CW, Robb L. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 2005, 104:2092-2098. 10.1002/cncr.21435, 16206293.
50. West JA, Viswanathan SR, Yabuuchi A, Cunniff K, Takeuchi A, Park I-H, Sero JE, Zhu H, Perez-Atayde A, Frazier AL, Surani MA, Daley GQ. A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature 2009, 460:909-913. 2729657, 19578360.
51. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science 2008, 320:97-100. 10.1126/science.1154040, 3368499, 18292307.
52. Zhao Y, Yin X, Qin H, Zhu F, Liu H, Yang W, Zhang Q, Xiang C, Hou P, Song Z, Liu Y, Yong J, Zhang P, Cai J, Liu M, Li H, Li Y, Qu X, Cui K, Zhang W, Xiang T, Wu Y, Zhao Y, Liu C, Yu C, Yuan K, Lou J, Ding M, Deng H. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 2008, 3:475-479. 10.1016/j.stem.2008.10.002, 18983962.
53. Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M, Blasco MA, Serrano M. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009, 460:1136-1139. 10.1038/nature08290, 19668188.
54. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Belmonte JC. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460:1140-1144. 10.1038/nature08311, 2735889, 19668186.
55. Marion RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460:1149-1153. 10.1038/nature08287, 19668189.
56. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009, 460:1145-1148. 10.1038/nature08285, 19668190.
57. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009, 460:1132-1135. 10.1038/nature08235, 2917235, 19668191.
58. Quinlan AR, Boland MJ, Leibowitz ML, Shumilina S, Pehrson SM, Baldwin KK, Hall IM. Genome sequencing of mouse induced pluripotent stem cells reveals retroelement stability and infrequent DNA rearrangement during reprogramming. Cell Stem Cell 2011, 9:366-373. 10.1016/j.stem.2011.07.018, 21982236.
59. Ji J, Ng SH, Sharma V, Neculai D, Hussein S, Sam M, Trinh Q, Church GM, McPherson JD, Nagy A, Batada NN. Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells. Stem Cells 2012, 30:435-440. 10.1002/stem.1011, 22162363.
60. Pasi CE, Dereli-Oz A, Negrini S, Friedli M, Fragola G, Lombardo A, Van Houwe G, Naldini L, Casola S, Testa G, Pasi CE, Dereli-Oz A, Negrini S, Friedli M, Fragola G, Lombardo A, Van Houwe G, Naldini L, Casola S, Testa G. Genomic instability in induced stem cells. Cell Death Differ 2011, 18:745-753. 10.1038/cdd.2011.9, 3079512,3079512, 21311564.
61. Cheng L, Hansen NF, Zhao L, Du Y, Zou C, Donovan FX, Chou B-K, Zhou G, Li S, Dowey SN, Ye Z, , Chandrasekharappa SC, Yang H, Mullikin JC, Liu PP. NISC Comparative Sequencing Program Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell 2012, 10:337-344. 10.1016/j.stem.2012.01.005, 22385660, NISC Comparative Sequencing Program.
62. Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Närvä E, Ng S, Sourour M, Hämäläinen R, Olsson C, Lundin K, Mikkola M, Trokovic R, Peitz M, Brüstle O, Bazett-Jones DP, Alitalo K, Lahesmaa R, Nagy A, Otonkoski T. Copy number variation and selection during reprogramming to pluripotency. Nature 2011, 471:58-62. 10.1038/nature09871, 21368824.
63. Mayshar Y, Ben-David U, Lavon N, Biancotti J-C, Yakir B, Clark AT, Plath K, Lowry WE, Benvenisty N. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010, 7:521-531. 10.1016/j.stem.2010.07.017, 20887957.
64. Michalak E, Villunger A, Erlacher M, Strasser A. Death squads enlisted by the tumour suppressor p53. Biochem Biophys Res Commun 2005, 331:786-798. 10.1016/j.bbrc.2005.03.183, 15865934.
65. Lake BB, Fink J, Klemetsaune L, Fu X, Jeffers JR, Zambetti GP, Xu Y. Context-dependent enhancement of induced pluripotent stem cell reprogramming by silencing Puma. Stem Cells 2012, 30:888-897. 10.1002/stem.1054, 22311782.
66. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011, 11:268-277. 10.1038/nrc3034, 21390058.
67. Choo AB, Tan HL, Ang SN, Fong WJ, Chin A, Lo J, Zheng L, Hentze H, Philp RJ, Oh SK, Yap M. Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells 2008, 26:1454-1463. 10.1634/stemcells.2007-0576, 18356574.
68. Tan HL, Fong WJ, Lee EH, Yap M, Choo A. mAb 84, a cytotoxic antibody that kills undifferentiated human embryonic stem cells via oncosis. Stem Cells 2009, 27:1792-1801. 10.1002/stem.109, 19544435.
69. Tang C, Lee AS, Volkmer J-P, Sahoo D, Nag D, Mosley AR, Inlay MA, Ardehali R, Chavez SL, Pera RR, Behr B, Wu JC, Weissman IL, Drukker M. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol 2011, 29:829-834. 10.1038/nbt.1947, 21841799.
70. Fujikawa T, Oh S-H, Pi L, Hatch HM, Shupe T, Petersen BE. Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol 2005, 166:1781-1791. 10.1016/S0002-9440(10)62488-1, 1602425, 15920163.
71. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003, 113:643-655. 10.1016/S0092-8674(03)00392-1, 12787505.
72. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003, 113:631-642. 10.1016/S0092-8674(03)00393-3, 12787504.
73. Moretto-Zita M, Jin H, Shen Z, Zhao T, Briggs SP, Xu Y. Phosphorylation stabilizes Nanog by promoting its interaction with Pin1. Proc Natl Acad Sci USA 2010, 107:13312-13317. 10.1073/pnas.1005847107, 2922169, 20622153.
74. Boyd AS, Rodrigues NP, Lui KO, Fu X, Xu Y. Concise review: immune recognition of induced pluripotent stem cells. Stem Cells 2012, 30:797-803. 10.1002/stem.1066, 22419544.
75. Stucker F, Marti HP, Hunger RE. Immunosuppressive drugs in organ transplant recipients--rationale for critical selection. Curr Probl Dermatol 2012, 43:36-48.
76. Schonder KS, Mazariegos GV, Weber RJ. Adverse effects of immunosuppression in pediatric solid organ transplantation. Pediatric Drugs 2010, 12:35-49. 10.2165/11316180-000000000-00000, 20034340.
77. Baron C, Forconi C, Lebranchu Y. Revisiting the effects of CMV on long-term transplant outcome. Curr Opin Organ Transplant 2010, 15:492-498. 10.1097/MOT.0b013e32833bd3b5, 20631617.
78. Lebedeva T, Dustin ML, Sykulev Y. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol 2005, 17:251-258. 10.1016/j.coi.2005.04.008, 15886114.
79. Felix NJ, Suri A, Salter-Cid L, Nadler SG, Gujrathi S, Corbo M, Aranda R. Targeting lymphocyte co-stimulation: From bench to bedside. Autoimmunity 2010, 43:514-525. 10.3109/08916931003674741, 20429850.
80. Isaacs JD. T cell immunomodulation' the Holy Grail of therapeutic tolerance. Curr Opin Pharmacol 2007, 7:418-425. 10.1016/j.coph.2007.05.001, 17611158.
81. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008, 224:166-182. 10.1111/j.1600-065X.2008.00662.x, 18759926.
82. Pearl JI, Lee AS, Leveson-Gower DB, Sun N, Ghosh Z, Lan F, Ransohoff J, Negrin RS, Davis MM, Wu JC. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2010, 8:309-317.
83. Turka LA, Wood K, Bluestone JA. Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia. Curr Opin Organ Transplant 2010, 15:441-448. 10.1097/MOT.0b013e32833bd371, 20631613.
84. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008, 358:362-368. 10.1056/NEJMoa074191, 18216356.
85. Vodyanik MA, Bork JA, Thomson JA, Slukvin II. Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 2005, 105:617-626. 10.1182/blood-2004-04-1649, 15374881.
86. Ledran MH, Krassowska A, Armstrong L, Dimmick I, Renström J, Lang R, Yung S, Santibanez-Coref M, Dzierzak E, Stojkovic M, Oostendorp RA, Forrester L, Lako M. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell 2008, 3:85-98. 10.1016/j.stem.2008.06.001, 18593561.
87. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 2011, 333:218-221. 10.1126/science.1201219, 21737740.
88. Aguila JR, Liao W, Yang J, Avila C, Hagag N, Senzel L, Ma Y. SALL4 is a robust stimulator for the expansion of hematopoietic stem cells. Blood 2011, 118:576-585. 10.1182/blood-2011-01-333641, 21602528.
89. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676. 10.1016/j.cell.2006.07.024, 16904174.
90. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872. 10.1016/j.cell.2007.11.019, 18035408.
91. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920. 10.1126/science.1151526, 18029452.
92. Park I-H, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146. 10.1038/nature06534, 18157115.
93. Yamanaka S. A fresh look at iPS cells. Cell 2009, 137:13-17. 10.1016/j.cell.2009.03.034, 19345179.
94. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Thomson JA. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009, 324:797-801. 10.1126/science.1172482, 2758053, 19325077.
95. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Schöler HR, Duan L, Ding S. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009, 4:381-384. 10.1016/j.stem.2009.04.005, 19398399.
96. Warren L, Manos PD, Ahfeldt T, Loh Y-H, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630. 10.1016/j.stem.2010.08.012, 20888316.
97. Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, Nishikawa S, Tanemura M, Mimori K, Tanaka F, Saito T, Nishimura J, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Doki Y, Mori M. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2010, 8:633-638.
98. Anokye-Danso F, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, Zhang Y, Yang W, Gruber PJ, Epstein JA, Morrisey EE. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2010, 8:376-388.
99. Zhu S, Li W, Zhou H, Wei W, Ambasudhan R, Lin T, Kim J, Zhang K, Ding S. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 2010, 7:651-655. 10.1016/j.stem.2010.11.015, 21112560.
100. Zhao T, Zhang Z-N, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
101. Shi Y, Desponts C, Do JT, Hahm HS, Schöler HR, Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008, 3:568-574. 10.1016/j.stem.2008.10.004, 18983970.
102. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, Muhlestein W, Melton DA. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008, 26:1269-1275. 10.1038/nbt.1502, 18849973.
103. Lin T, Ambasudhan R, Yuan X, Li W, Hilcove S, Abujarour R, Lin X, Hahm HS, Hao E, Hayek A, Ding S. A chemical platform for improved induction of human iPSCs. Nat Methods 2009, 6:805-808. 10.1038/nmeth.1393, 19838168.
104. Esteban MA, Wang T, Qin B, Yang J, Qin D, Cai J, Li W, Weng Z, Chen J, Ni S, Chen K, Li Y, Liu X, Xu J, Zhang S, Li F, He W, Labuda K, Song Y, Peterbauer A, Wolbank S, Redl H, Zhong M, Cai D, Zeng L, Pei D. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 2010, 6:71-79. 10.1016/j.stem.2009.12.001, 20036631.
105. Wang Q, Xu X, Li J, Liu J, Gu H, Zhang R, Chen J, Kuang Y, Fei J, Jiang C, Wang P, Pei D, Ding S, Xie X. Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells. Cell Res 2011, 21:1424-1435. 10.1038/cr.2011.108, 3193456, 21727907.
106. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, Jaenisch R. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318:1920-1923. 10.1126/science.1152092, 18063756.
107. Xu D, Alipio Z, Fink LM, Adcock DM, Yang J, Ward DC, Ma Y. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci USA 2009, 106:808-813. 10.1073/pnas.0812090106, 2630078, 19139414.
108. Liu H, Kim Y, Sharkis S, Marchionni L, Jang Y-Y. In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med 2011, 3. 82ra39.
109. Swijnenburg R-J, Tanaka M, Vogel H, Baker J, Kofidis T, Gunawan F, Lebl DR, Caffarelli AD, de Bruin JL, Fedoseyeva EV, Robbins RC. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005, 112:I-166-172.
110. Robertson NJ, Brook FA, Gardner RL, Cobbold SP, Waldmann H, Fairchild PJ. Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc Natl Acad Sci USA 2007, 104:20920-20925. 10.1073/pnas.0710265105, 2409242, 18093946.
111. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
112. Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, Herb B, Ladd-Acosta C, Rho J, Loewer S, Miller J, Schlaeger T, Daley GQ, Feinberg AP. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009, 41:1350-1353. 10.1038/ng.471, 2958040, 19881528.
113. Deng J, Shoemaker R, Xie B, Gore A, LeProust EM, Antosiewicz-Bourget J, Egli D, Maherali N, Park I-H, Yu J, Daley GQ, Eggan K, Hochedlinger K, Thomson J, Wang W, Gao Y, Zhang K. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol 2009, 27:353-360. 10.1038/nbt.1530, 2715272, 19330000.
114. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O'Malley R, Castanon R, Klugman S, Downes M, Yu R, Stewart R, Ren B, Thomson JA, Evans RM, Ecker JR. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011, 471:68-73. 10.1038/nature09798, 3100360, 21289626.
115. Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 2009, 5:237-241. 10.1016/j.stem.2009.08.001, 19716359.
116. Liu D, Xu Y. p53, oxidative stress, and aging. Antioxid Redox Signal 2011, 15:1669-1678. 10.1089/ars.2010.3644, 21050134.
117. Stadtfeld M, Apostolou E, Akutsu H, Fukuda A, Follett P, Natesan S, Kono T, Shioda T, Hochedlinger K. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010, 465:175-181. 10.1038/nature09017, 20418860.
118. Stadtfeld M, Apostolou E, Ferrari F, Choi J, Walsh RM, Chen T, Ooi SSK, Kim SY, Bestor TH, Shioda T, Park PJ, Hochedlinger K. Ascorbic acid prevents loss of Dlk1-Dio3 imprinting and facilitates generation of all-iPS cell mice from terminally differentiated B cells. Nat Genet 2012, 44:398-405. 10.1038/ng.1110, 22387999.